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Virulence factors, such as the recently discovered PB1-F2, contribute to the pathogenesis and co-
morbidity of influenza A virus. In this issue of Cell Host & Microbe, McAuley et al. characterize the
role of PB1-F2, including in the pandemic 1918 virus, in causing increased lung pathology and fatal
pneumococcus infection in mice. This work sheds light on the mechanisms of pathogenicity during
influenza A virus infections.Influenza A virus is an important path-
ogen worldwide. During years of pan-
demic influenza outbreaks there is sig-
nificant morbidity and mortality that
can influence entire countries’ econo-
mies. The most deadly recorded pan-
demic, in 1918–1919, killed on the or-
der of 50 million people worldwide,
and many of those deaths are thought
to have been caused by secondary
bacterial pneumonia (Beveridge, 1991;
Johnson and Mueller, 2002; Nguyen-
Van-Tam and Hampson, 2003). Histor-
ically, secondary bacterial pneumonia
is the leading cause of influenza-re-
lated deaths; however, most studies
on influenza pathogenesis focus ex-
clusively on virally induced pathology,
morbidity, andmortality. In this issue of
Cell Host & Microbe, McAuley et al.
(2007) describe a new virulence factor
(PB1-F2) contributing to secondary
bacterial infection and comorbidity
after influenza A virus infection.
In order to identify the proteins that
contribute to pathogenesis during nat-
ural influenza infections, it is important
to examine the effect of viral factors on
the susceptibility of the host to sec-ondary bacterial infections. Research
into virulence factors of influenza has
been extensive over recent years.
Focus on this topic has increased, in
some part, due to the threat of an
impending pandemic by H5N1 avian
viruses. Many researchers believe
that a new pandemic is imminent,
and the more we know about the path-
ogenicity of the influenza A virus, the
better prepared we will be to control
and treat pandemic infections.
PB1-F2 is the most recently discov-
ered influenza A virus protein and con-
tributes toviral pathogenesis (Figure1).
PB1-F2 was discovered through a
search for novel peptides presented
to CD8+ T cells during influenza A virus
infection (Chen et al., 2004). PB1-F2
induces apoptosis by localizing to the
inner and outer mitochondrial mem-
branes through a nontraditional mito-
chondrial targeting sequence in the
C-terminal region of the protein (Gibbs
et al., 2003). In themitochondrial mem-
brane, PB1-F2 interactswith ANT3and
VDAC1, punching holes into the mito-
chondrial membrane and causing
cytochrome c release (Zamarin et al.,Cell Host & Microbe2005). The C-terminal region has also
been found through crystallization
studies to have an a-helical structure,
which might be important for the proa-
poptotic function (Bruns et al., 2007).
The mitochondrial function of PB1-F2
in vitro has been investigated by multi-
ple groups, but until recently little re-
search has been done to investigate
the function of PB1-F2 in vivo. Work
by Zamarin et al. (2006) showed the
impacts of PB1-F2 during influenza A
virus infection in the mouse model. In
these studies Zamarin and colleagues
showed that a mildly pathogenic virus
in mice had decreased pathogenicity
whenPB1-F2expressionwasknocked
out. These results demonstrated the
ability of this small protein to impact
the outcome of influenza A virus infec-
tions in mice.
McAuley et al. (2007) have charac-
terized the effects of PB1-F2 on sec-
ondary bacterial infections in addition
to analyzing the contribution of the
PB1-F2 from the 1918 pandemic virus
to virulence. The paper defines the
role of PB1-F2 in the establishment of
fatal secondary bacterial pneumonia.2, October 2007 ª2007 Elsevier Inc. 207
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(Top left) The severity of secondary bacterial pneumonia caused by Streptococcus pneumoniae is increased when the infecting influenza A virus con-
tains full-length PB1-F2 (photograph depictsmicewith pneumonia that are coinfectedwith influenza A virus andS. pneumoniae expressing luciferase;
McAuley et al., 2007). (Top right) The presence of PB1-F2 from the 1918 pandemic virus increases lung pathology and causes increased neutrophil
and lung infiltration (drawing depicts lung infected with 1918 pandemic influenza A virus; courtesy of the National Museum of Health and Medicine,
Armed Forces Institute of Pathology, Washington, D.C. [Schwarz1919_RedLungPneumonia]; http://www.nmhm.washingtondc.museum/collections/
archives/agalleries/1918flu/Red_lung_pneumonia_Schwarz_1919_front.jpg). (Bottom right) Apoptosis has been demonstrated via the interaction of
PB1-F2 (purple) with ANT3 (red cylinder) and VDAC1 (blue cylinder) in the mitochondria through cytochrome c (red dots) release. (Bottom left) PB1-F2
increases pathogenesis and causes cytokine dysregulation in the mouse model.The presence of PB1-F2 in the mouse-
adapted PR8 influenza A virus en-
hances the development of secondary
bacterial pneumonia from Streptococ-
cus pneumoniae in mice and de-
creases survival. Mice challenged with
S. pneumoniae had severe lung dam-
age and hypercytokinemia in addition
to increased bacterial load in the lungs
compared to mice infected with PR8
virus lacking PB1-F2. This difference
in pathogenicity can be linked to
the increased number of neutrophils,
macrophages, and T cells in the bron-
choalveolar lavage fluid (BALF) from
infectedmice on day 7 post-viral infec-
tion (McAuley et al., 2007). The find-
ings presented are important because
they show that, while PB1-F2might not
impact the pathogenicity of all strains
of influenza A viruses, there is an im-
pact on comorbidity during secondary
bacterial infection. These studies high-
light the importance of modeling all
aspects of human influenza in mice.208 Cell Host & Microbe 2, October 2007To further elucidate the role of PB1-F2
in enhancing secondary bacterial infec-
tions, McAuley et al. (2007) synthesized
a C-terminal PB1-F2 peptide and
administered it to mice intranasally. Un-
expectedly, the peptide caused an in-
crease in macrophages and neutrophils
in the lungs similar to that induced by
wild-type PR8 infection. When infection
with S. pneumoniae was performed, all
of themice given the C-terminal peptide
succumbed to infection, whereas all
mice given a control peptide of the N-
terminal portion of PB1-F2 survived
without any signs of morbidity. This
striking difference in morbidity and sur-
vival implicates PB1-F2 as a major con-
tributor to complicating secondary
bacterial infections through increasing
immune cell infiltration of the lungs.
Based on their data showing that the
PB1-F2 of influenza A virus contributes
to pathogenesis and the outcome of
secondary bacterial infections, McAu-
ley et al. (2007) hypothesized that theª2007 Elsevier Inc.introduction of the PB1-F2 of a highly
pathogenic virus into the background
of a low-pathogenicity virus could lead
to an increase in pathogenicity. To test
their hypothesis, the PB1-F2 of the
1918 virus was engineered into the
PR8 virus by making eight amino acid
changes that do not alter the PB1 pro-
tein, and the resulting virus was subse-
quently inoculated into mice. PB1-F2
from the 1918 virus makes the PR8 vi-
rus more deadly both with and without
secondary bacterial infection. These
data suggest that the PB1-F2 from
the 1918 pandemic virus could have
contributed to its high virulence and
mortality rate by causing a more se-
vere viral infection and exacerbating
any resulting secondary bacterial
pneumonia.
New work by Conenello et al. (2007)
has identified a specific amino acid
that contributes to increased pathoge-
nicity. The single amino acid change
was evaluated in a fully reconstructed
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further support the conclusions made
by McAuley et al. that the PB1-F2 of
1918 virus contributes to the extreme
virulence of the virus inmice. However,
none of the recent work on PB1-F2
and more specifically on the PB1-F2
of the 1918 pandemic virus provides
a molecular mechanism for the ability
of the 1918 PB1-F2 to cause macro-
phage and neutrophil infiltration into
the lung or increase morbidity. Fur-
thermore, there have been no studies
connecting the known apoptotic func-
tion of PB1-F2 in vitro to the increased
in vivo pathogenesis, or to the ability
of PB1-F2 to bind PB1 (S. Ludwig,
personal communication).
It seems the more we know about
PB1-F2, the more puzzling questions
there are to ponder. Howcouldwepre-
vent thedetrimental effects ofPB1-F2?
Would it be possible to inhibit the activ-Orchestration of
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ChronicHelicobacter pylori infec
cancer. In order to survive and p
ogen has evolved numerous mea
light on mechanisms by which H
facilitate its persistence within th
Helicobacter pylori (H. pylori) has in-
fected human stomachs for more
than 55,000 years, with colonization
typically lasting for the lifetime of its
host (Linz et al., 2007). This bacterium
colonizes more than 50% of the
world’s population, thereby establish-
ing itself as one of the most successful
human pathogens. H. pylori has devel-
oped numerous strategies to colonize
and thrive within the hostile environ-ity of PB1-F2 through smart design
of small-molecule drugs? What role
does cytokine dysregulation have in in-
creasing lung pathology, and can we
prevent it by abrogating the function
of PB1-F2? Exactly how is the C-termi-
nal PB1-F2 peptide getting into cells
to impact cell recruitment, or alterna-
tively, isC-terminal PB1-F2evenenter-
ing cells at all? Lastly, could this pep-
tide or full-length PB1-F2 be found
extracellularly in a natural infection?
Truly exciting work is now being done
with PB1-F2, but there are still many
holes in the knowledge we have about
influenza’s smallest protein.
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